Neokestose

Neokestose (1-100 μg; 5 min) dose-dependently inhibits purified Candida sp. invertase activity, with 14.7% inhibition at the 100 μg concentration tested^[1].
Neokestose (100 μg; 1 h for crude intestinal enzyme; 1-100 μg; 5 min for invertase) is stable to enzymatic digestion by crude α-glycosidase solution from rat intestinal acetone powder and purified Candida sp. invertase under the tested conditions^[1].
Neokestose (80 μg/mL; 0-240 min) is hydrolyzed in pH 1 artificial gastric juice at 37 °C, with ~80% decomposed after 240 min, producing glucose, fructose, sucrose, and blastose (peaking at 1.2 μM at 180 min)^[1].
Neokestose (0.5-2.5 mg/mL; 48 h) dose-dependently reduces the viability of human colorectal cancer Caco-2 cells, with viability dropping to ~59% at the highest tested concentration of 2.5 mg/mL following 48 h of treatment^[3].
Neokestose (0.5-2.5 mg/mL; 48 h) dose-dependently increases the sub-G1 phase population of human colorectal cancer Caco-2 cells, reaching 45% at 2.5 mg/mL following 48 h of treatment, indicating induced apoptosis^[3].
Neokestose (0.5-2.5 mg/mL; 48 h) dose-dependently increases the percentage of late apoptotic human colorectal cancer Caco-2 cells, reaching 31.2% at 2.5 mg/mL following 48 h of treatment^[3].
Neokestose (0.5-2.5 mg/mL; 48 h) dose-dependently inhibits the expression of NF-κB and COX-2 proteins in human colorectal cancer Caco-2 cells following 48 h of treatment^[3].
Neokestose (10% (w/v) sucrose; 24 h inoculum, 18 h fermentation) was produced at 107.63 g/L by Xanthophyllomyces dendrorhous TISTR 5730 fermenting longan fruit pulp extract, achieving a productivity of 5.98 g/L•h^[4].
Neokestose (0.5% (w/v) sucrose inoculum, 20% (v/v) cell pellet; 96 h) was purified from fermented longan fruit pulp extract by Candida orthopsilosis FLA44.2 to 98.3% purity, with 97.5% neokestose recovery and no detectable glucose or sucrose^[4].
Neokestose (2 min oral, 3 h gastric, 270 h intestinal phases) is resistant to simulated human gastrointestinal digestion, retaining over 95% of its initial content after exposure to oral, gastric, and intestinal conditions^[4].
Neokestose (20 g/L; 48 h) is readily fermentable by Lacticaseibacillus casei TISTR 1500, L. casei TISTR 1463, and Lactiplantibacillus plantarum TISTR 1465, supporting growth equivalent to glucose and being fully consumed within 24-36 h of incubation^[4].
Neokestose (5-20% (w/v); 48 h) is non-cytotoxic to HIEC-6 human small intestinal epithelial cells, showing no significant reduction in cell viability after 48 h incubation^[4].
Neokestose (10 g/L; 24 h) is preferentially utilized by Bifidobacterium breve NCFB 2257, Bifidobacterium longum NCFB 2259, Bifidobacterium adolescentis NCFB 2230, and Bifidobacterium infantis NCFB 2205 under anaerobic conditions, supporting significantly higher biomass production (1.14-1.17 g/L) than facultative anaerobes or Lactobacillus salivarius NCFB 1555, with utilization rates ranging from 68.7-98.9%^[5].
Neokestose (10 g/L; 5-24 h) preferentially stimulates the growth of beneficial bifidobacteria and lactobacilli in human faecal microbiota batch cultures, reduces populations of potentially harmful coliforms, bacteroides, clostridia, and gram-positive cocci after 24 h^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.